EGFR and colorectal carcinoma: Approximately 40% of CRC patients have KRAS mutations, while about 6% have NRAS mutations leading to the constitutive activation of Ras-Raf-mitogen-activated protein kinase (MAPK) signaling pathway, downstream of the epidermal growth factor receptor (EGFR) (1, 2).